Nec‐1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive symptoms of learning and memory deficits. Such cognitive impairments are attributed to brain atrophy resulting from progressive neuronal and synaptic loss; therefore, alleviation of neural cell death is as an important target of treatment as other classical hallmarks of AD, such as aggregation of amyloid‐β (Aβ) and hyperphosphorylation of tau. Here, we found that an anti‐necroptotic molecule necrostatin‐1 (Nec‐1) directly targets Aβ and tau proteins, alleviates brain cell death and ameliorates cognitive impairment in AD models. In the cortex and hippocampus of APP/PS1 double‐transgenic mice, Nec‐1 treatment reduced the levels of Aβ oligomers, plaques and hyperphosphorylated tau without affecting production of Aβ, while it altered the levels of apoptotic marker proteins. Our results showing multiple beneficial modes of action of Nec‐1 against AD provide evidence that Nec‐1 may serve an important role in the development of preventive approach for AD.

[1]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[2]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[3]  F. Chan,et al.  RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation , 2011, PloS one.

[4]  Y. Ihara,et al.  Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. , 1998, The American journal of pathology.

[5]  Dong Jin Kim,et al.  Regulation of in vitro Aβ1-40 aggregation mediated by small molecules. , 2010, Journal of Alzheimer's disease : JAD.

[6]  Sokratis G. Papageorgiou,et al.  Current and future treatments for Alzheimer’s disease , 2013, Therapeutic advances in neurological disorders.

[7]  Dong Jin Kim,et al.  Efficient access to highly pure β-amyloid peptide by optimized solid-phase synthesis , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[8]  Samir Guglani.  Death , 1890, The Lancet.

[9]  Y. Ihara,et al.  Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques , 1998, Acta Neuropathologica.

[10]  V. Dixit,et al.  Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis. , 2001, Journal of cell science.

[11]  K. Garber.  Genentech's Alzheimer's antibody trial to study disease prevention , 2012, Nature Biotechnology.

[12]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[13]  C. Parsons,et al.  The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence , 2003, International journal of geriatric psychiatry.

[14]  Dong Jin Kim,et al.  Amelioration of Alzheimer’s disease by neuroprotective effect of sulforaphane in animal model , 2013, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  Hong-Qi Yang,et al.  Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau , 2012, Translational Neurodegeneration.

[16]  Yasuo Ihara,et al.  Amyloid β‐protein deposition in the leptomeninges and cerebral cortex , 1997 .

[17]  Mary Sano,et al.  Preventing Alzheimer’s Disease , 2008, CNS drugs.

[18]  Alexei Degterev,et al.  Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury , 2005, Nature chemical biology.

[19]  Younan Xia,et al.  The differentiation of embryonic stem cells seeded on electrospun nanofibers into neural lineages. , 2009, Biomaterials.

[20]  Bradley T. Hyman,et al.  Human LilrB2 Is a β-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimer’s Model , 2013, Science.

[21]  D. Kang,et al.  Necrostatin-1 Ameliorates Intracerebral Hemorrhage-Induced Brain Injury in Mice Through Inhibiting RIP1/RIP3 Pathway , 2015, Neurochemical Research.

[22]  G. Bitan,et al.  Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assemblies. , 2004, Accounts of chemical research.

[23]  Holger Jahn,et al.  Memory loss in Alzheimer's disease , 2013, Dialogues in clinical neuroscience.

[24]  H. Kim,et al.  Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits. , 2016, Journal of visualized experiments : JoVE.

[25]  C. Matrone,et al.  Apoptosis and in vitro Alzheimer’s disease neuronal models , 2009, Communicative & integrative biology.

[26]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[27]  S. Deweerdt.  Prevention: Activity is the best medicine , 2011, Nature.

[28]  P. Vandenabeele,et al.  Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models , 2012, Cell Death and Differentiation.

[29]  D. Borchelt,et al.  Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities , 2005, Neurobiology of Disease.

[30]  T. Zako,et al.  Amyloid oligomers: formation and toxicity of Aβ oligomers , 2010, The FEBS journal.

[31]  Benedetto Sacchetti,et al.  Role of dorsal hippocampus in acquisition, consolidation and retrieval of rat's passive avoidance response: a tetrodotoxin functional inactivation study , 1996, Brain Research.

[32]  D. Dhanasekaran,et al.  JNK signaling in apoptosis , 2008, Oncogene.

[33]  Xiongwei Zhu,et al.  Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy , 2012, International journal of Alzheimer's disease.

[34]  B. Reif,et al.  Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization , 2010, Proceedings of the National Academy of Sciences.

[35]  F. Pohlenz,et al.  Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices. , 2007, Optics letters.

[36]  P. Greengard,et al.  Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Westaway,et al.  Dense-core and diffuse Abeta plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy. , 2007, Biopolymers.

[38]  P. Scheltens,et al.  Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. , 2004, Neurology.

[39]  M. Ciotti,et al.  Endogenous Aβ causes cell death via early tau hyperphosphorylation , 2011, Neurobiology of Aging.

[40]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[41]  D. Hunting,et al.  Probing the interactions of the solvated electron with DNA by molecular dynamics simulations: bromodeoxyuridine substituted DNA , 2008, Journal of molecular modeling.

[42]  G. Bitan.  Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. , 2006, Methods in enzymology.

[43]  Y. Bae,et al.  TREK-1 and Best1 Channels Mediate Fast and Slow Glutamate Release in Astrocytes upon GPCR Activation , 2012, Cell.

[44]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[45]  Yigong Shi,et al.  Structural basis of RIP1 inhibition by necrostatins. , 2013, Structure.

[46]  P. Liberski,et al.  Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. , 2004, Acta neurobiologiae experimentalis.

[47]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[48]  Dong Jin Kim,et al.  Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[49]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[50]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[51]  A. Miranker,et al.  Protein-induced photophysical changes to the amyloid indicator dye thioflavin T , 2010, Proceedings of the National Academy of Sciences.

[52]  D. Walsh,et al.  Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases , 2008, Molecular medicine.

[53]  Philippe Juin,et al.  Bax activation and mitochondrial insertion during apoptosis , 2007, Apoptosis.

[54]  Y. Zhang,et al.  Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease , 2011, Cell Death and Disease.

[55]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[56]  K. Double,et al.  Topography of brain atrophy during normal aging and alzheimer's disease , 1996, Neurobiology of Aging.

[57]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[58]  G. Salvesen,et al.  Caspases: opening the boxes and interpreting the arrows , 2002, Cell Death and Differentiation.

[59]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[60]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[61]  Dong Jin Kim,et al.  EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques , 2015, Nature Communications.

[62]  Zhang Qinli,et al.  Necrostatin-1 inhibits the degeneration of neural cells induced by aluminum exposure. , 2013, Restorative neurology and neuroscience.

[63]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[64]  Hirohisa Tajima,et al.  Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. , 2006, Current neuropharmacology.

[65]  Kenta Moriwaki,et al.  The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis , 2012, Cell.

[66]  K. Reymann,et al.  Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity , 2010, Proceedings of the National Academy of Sciences.

[67]  Xi-ping Chen,et al.  Necrostatin-1 Suppresses Autophagy and Apoptosis in Mice Traumatic Brain Injury Model , 2012, Neurochemical Research.

[68]  Y. Ihara,et al.  Amyloid beta-protein deposition in the leptomeninges and cerebral cortex. , 1997, Annals of neurology.

[69]  C. Belka,et al.  Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology , 2002, International journal of radiation biology.

[70]  G. Carter,et al.  Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer’s disease , 2013, BMC Genomics.